Savara (SVRA) Current Assets (2010 - 2026)
Savara (SVRA) posted quarterly Current Assets of $209.3 million for Q1 2026, up 17.93% year-over-year from $177.4 million in Q1 2025, and down 13.39% quarter-over-quarter from $241.6 million in Q4 2025.
Savara (SVRA) Current Assets (2010 - 2026) Analysis & Trends
Savara (SVRA) has reported Current Assets for 17 consecutive years, with $209.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Current Assets rose 17.93% year-over-year to $209.3 million; the TTM figure through Mar 2026 stood at $209.3 million (up 17.93% YoY), while the FY2025 annual figure was $241.6 million, up 19.53% from the prior year.
- Current Assets eased to $209.3 million in Q1 2026 per SVRA's latest filing, from $241.6 million in the prior quarter.
- Across five years, Current Assets topped out at $241.6 million in Q4 2025 and bottomed at $107.9 million in Q2 2023.
- Historically, Current Assets has averaged $161.0 million across 5 years, with a median of $151.0 million in 2025.
- Annual changes were most pronounced in 2024 — Current Assets surged 33.1% — and 2025, when it plunged 43.37%.
- Savara's Current Assets stood at $129.0 million in 2022, then advanced by 28.69% to $165.9 million in 2023, then rose by 21.81% to $202.1 million in 2024, then grew by 19.53% to $241.6 million in 2025, then dropped by 13.39% to $209.3 million in 2026.
- Business Quant data shows SVRA's Current Assets at $209.3 million in Q1 2026, $241.6 million in Q4 2025, and $128.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 8.07 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.03 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 7.22 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 11.83 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 1.76 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.62 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.63 Bn |
| 10 | Savara | 1.11 Bn | 1.11 Bn | - | 178.32 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 178.32 Mn |
| Mar 31, 2026 | 209.27 Mn |
| Dec 31, 2025 | 241.62 Mn |
| Sep 30, 2025 | 128.20 Mn |
| Jun 30, 2025 | 150.99 Mn |
| Mar 31, 2025 | 177.44 Mn |
| Dec 31, 2024 | 202.14 Mn |
| Sep 30, 2024 | 226.40 Mn |
| Jun 30, 2024 | 127.69 Mn |
| Mar 31, 2024 | 146.19 Mn |
| Dec 31, 2023 | 165.95 Mn |
| Sep 30, 2023 | 170.10 Mn |
| Jun 30, 2023 | 107.90 Mn |
| Mar 31, 2023 | 117.63 Mn |
| Dec 31, 2022 | 128.95 Mn |
| Sep 30, 2022 | 137.07 Mn |
| Jun 30, 2022 | 145.39 Mn |
| Mar 31, 2022 | 154.54 Mn |
| Dec 31, 2021 | 165.00 Mn |
| Sep 30, 2021 | 174.58 Mn |